iX Biopharma has issued new shares to convert a US$1.2 million debt to preserve cash for its strategic expansion in the US. The move comes as the company holds a significant US$41 million development contract with the US government for its pain management drug, Wafermine.
Company Information
Company
iX Biopharma
Location
Singapore
About
iX Biopharma is a pharmaceutical company listed on Catalist, focusing on innovative pain management solutions. Its patented product, Wafermine, is a non-opioid sublingual ketamine wafer for treating acute moderate to severe pain. The company is also expanding its commercial presence in the US market.
Predictive Intelligence
Strategic
ML-powered predictions for iX Biopharma's next move
SingaporeManufacturingBiotechnologyHealth CarePharmaceutical